An interventional study of Percutaneous Tibial Nerve Stimulation in Faecal Incontinence With Faecal Urgency, Rectal Cancer and Radiotherapy Side Effects, sponsored by Region Skane. Not yet recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Region Skane · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Rectal Neoplasms with a site in Sweden — 15 open to participants now, 22 under way, 4 of them phase 3. Rectal Neoplasms · Sweden.
Among the 64 studies in Rectal Neoplasms with a site in Sweden, this one is the 30th largest by planned enrollment of the 40 interventional ones that give a count, is the only one that started in 2026, is one of 20 with no phase, reaches primary completion later than 19 of the 21 other live ones, and was the 64th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →15 of the 64 studies in Rectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Sweden, United States, Canada and 6 more countries
Ages 18+
Alexander Valdman · Sites in Sweden
Ages 18+
NanoEcho AB · Sites in Sweden
Ages 18–99 · Healthy volunteers
Skane University Hospital · Sites in Sweden
Ages 18+
Region Skane · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 11 · Phase 4 1
First in 1998; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 233 across the 40 interventional studies, 142 across the 23 observational. Of the 34 that completed or were terminated, 6 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 64 have an industry lead sponsor. The 10 most frequent:
Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.
Region Skane has 5 studies filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Rectal Neoplasms with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02945566Phase 3University of BirminghamCan we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? | 2027-08 |
| NCT04726800Anna MartlingCirculating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study | 2026-12 |
| NCT02669992Karolinska University HospitalLoop Ileostomy Closure:Stapled or Hand-sewn Anastomoses? Suture or Mesh Closure of the Stoma Site? | 2026-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 64 studies in Rectal Neoplasms with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to assess and evaluate the clinical efficacy of an intensified form of Percutaneous tibial nerve stimulation (PTNS) compared to standard conservative treatment for low anterior resection syndrome (LARS). A syndrome with symptoms such as faecal incontinence (FI), urgency to defecate and frequent bowel movements. Focus will be mainly on patients with significant faecal incontinence.
Participants will be randomized into 2 groups: Standard Care with bowel regulation or to High Intensive PTNS for 6 weeks.
Every treatment session will be at the clinic and take 30 minutes.
Standard care PTNS participants will have nurse contact once per week for 6 weeks
High Intensive PTNS participants will start with 5 sessions per week, which will the be phased out to 2 sessions per weeks during the 6 week period.
Follow up visits to the clinic will be at 3, 6 and 12 months after completion of study.
Patients in the Standard group whose symtoms have not improved significantly, will be given the option to try the High Intensive treatment option.
The HIPLARS study is a Swedish clinical research project investigating whether an intensive form of Percutaneous Tibial Nerve Stimulation (PTNS) can improve faecal incontinence (FI) in patients who develop Low Anterior Resection Syndrome (LARS) after rectal cancer surgery. LARS commonly causes frequent bowel movements, urgency, and faecal incontinence, which can significantly reduce quality of life.
All participants receive the current standard treatment for FI, including bowel management, pelvic floor exercises, biofeedback, and, if needed, mini-enemas. The study compares this standard treatment with an intensified PTNS treatment, a minimally invasive nerve stimulation therapy that may provide longer-lasting symptom relief. Participants whose symptoms persist after six months may also be offered PTNS.
The study will include approximately 60 participants across three Swedish clinics and lasts 12 months. Depending on the assigned study group, participants will attend 17-29 clinic visits and receive 12-24 PTNS treatment sessions, each lasting about 30 minutes. Assessments include medical examinations, ultrasound, questionnaires, quality-of-life surveys, and bowel diaries.
Participation is voluntary, and participants may withdraw at any time without affecting their future medical care. Researchers may also end participation for medical reasons or if study procedures are not followed.
PTNS is already an established treatment with a low risk of side effects. Possible risks include mild discomfort from the needle insertion and occasional minor bleeding at the insertion site. Serious side effects are uncommon.
Personal and medical information will be kept confidential, stored securely, and handled in accordance with GDPR and Swedish law. Study results may be published, but participants' identities will remain confidential.
The study is conducted by the Pelvic Floor Centre, Department of Surgery, Skåne University Hospital (SUS) Malmö, has been approved by the Swedish Ethical Review Authority, and is covered by standard patient and pharmaceutical insurance. Participants can contact the study team at any time with questions or concerns.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Conservative treatment for faecal incontinence. Mainly bowel regulation
24 treatment sessions av Percutaneous Tibial Nerve Stimulation
Procedure: Percutaneous Tibial Nerve Stimulation
A total of PTNS 24 sessions, with 5 PTNS sessions per week (30 min each) for 4 weeks, thereafter 2 sessions per week for 2 weeks.
Also known as: PTNS
Change in Low Anterior Resection Syndrome Score
The primary outcome classifies patients as responders or non-responders, with a responder defined as someone having a change of the LARS score from Major LARS to Minor or No LARS
Time frame: Outcome measures to be assessed at baseline, after 6 weeks, 3 months and 6 month treatment being the primary end point.
Improvement or change of at least 50 per cent in the number faecal incontinence episodes
An achievement of ≥ 50% change in weekly faecal incontinence episodes (FIEs) for secondary outcome
Time frame: Outcome measures to be assessed at baseline, after 6 weeks, 3 months and 6 month treatment being the primary end point.
Plan to share: No — Basically the Ethical clearance for the study does not accomodate sharing of IPD. Further, the study focuses mainly on cancer patients which is a sensitive patient group with regards to symtoms being examined in the study.
Start is estimated for Oct 2026; primary completion for Oct 2029, 35 months later.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 35 months is below that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.